Status:

COMPLETED

Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

Lead Sponsor:

GlaxoSmithKline

Conditions:

Tetanus

Hepatitis B

Eligibility:

All Genders

56-83 years

Phase:

PHASE3

Brief Summary

The primary purpose of this study is to demonstrate the lot-to-lot consistency of 3 production lots of GSK Biologicals' Hib-MenAC (Haemophilus influenzae type b and meningococcal serogroups A and C) v...

Detailed Description

The study is double blind. However the active control vaccine Tritanrix™-HepB/Hiberix™ will be administered in a single-blind manner. Blood samples will be collected for immunogenicity analyses. GSK B...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • healthy male or female, between, and including, 56 and 83 days of age.
  • Born after a gestation period between 36 and 42 weeks
  • Birth dose of hepatitis B vaccine within the first 72 hours of life
  • Exclusion criteria:
  • planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period.
  • Bacille Calmette-Guérin (BCG) vaccine received after the first 2 weeks of life.
  • History of OR previous vaccination against OR known exposure since birth to diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or meningococcal disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
  • A family history of congenital or hereditary immunodeficiency
  • History of any neurologic disorders or seizures
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine

Exclusion

    Key Trial Info

    Start Date :

    February 1 2006

    Trial Type :

    INTERVENTIONAL

    End Date :

    November 1 2006

    Estimated Enrollment :

    800 Patients enrolled

    Trial Details

    Trial ID

    NCT00197275

    Start Date

    February 1 2006

    End Date

    November 1 2006

    Last Update

    October 7 2016

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    GSK Investigational Site

    Bangkok, Thailand, 10400

    2

    GSK Investigational Site

    Khon Kaen, Thailand, 40002

    3

    GSK Investigational Site

    Songkhla, Thailand, 90110